Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00065312 |
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Non-Insulin-Dependent |
Drug: naveglitazar |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 5837, H7R-MC-GCBD |
Study First Received: | July 21, 2003 |
Last Updated: | July 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00065312 |
Health Authority: | United States: Food and Drug Administration |
Type 2 diabetes |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders |